SPECT/CT PROSTASCINT imaging guides prostate cancer therapy

11/4/2009 | Reuters

SPECT/CT images of PROSTASCINT, a monoclonal antibody attached to the radioisotope Indium-111 for specific targeting of prostate-specific membrane antigen, helped identify areas that needed increased doses of radioactive seeds in patients at risk for metastatic prostate cancer. The images also helped in evaluating for biochemical disease-free survival by showing the presence or absence of lymph node metastases.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Market Intelligence Manager
Olympus Corporation of the Americas
Southborough, MA
Regulatory Counsel
Food and Drug Administration
Silver Spring, MD
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Vice President, Commercial Markets
Meridian Health
Neptune, NJ
Health Plan CEO – Oregon
Trillium Community Health Plan
Eugene, OR